Accelr8 Posted Flat Q3 Revenue as R&D Spend Was Cut in Half and Losses Narrowed 40 Percent | GenomeWeb
NEW YORK (GenomeWeb News) — Accelr8 last week reported that third-quarter revenues were stable while R&D spending fell by half and losses narrowed 40 percent.
 
Total receipts for the three months ended April 30 increased to $22,700 from $19,800 year over year.
 
The company’s only revenue came from its OptiChem product line.
  
R&D spending was slashed to $247,500 from $490,000 year over year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.